Announced Date: 2024-10-16 (October 16, 2024)
Asset Name: Undisclosed
Licensor (Seller): Chengdu Baiyu Pharmaceutical (China)
Licensee (Buyer): Novartis
.
Asset Modality: Small Molecule
Asset Target: Undisclosed
Current Stage: Undisclosed
.
Scope of Authority:
Novartis has been granted an exclusive worldwide license for the development and commercialization of this asset.
.
Payment Detail:
Baiyu will receive
Upfront payment of $70 million,
Development, regulatory and commercial milestones payments of up to $1.1 billion.
Tiered royalties.
.
Link:
.
Note:
Chinese Name of Chengdu Baiyu, 成都百裕
